Rhenovia Aims To Boost Biosimulation Use In CNS R&D
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.